OMRON Healthcare and UCSF launch AFib trial

▴ OMRON Healthcare
Study will explore early detection of atrial fibrillation to reduce stroke and heart failure risk through home blood pressure monitoring.

KYOTO, Japan, Apr 2, 2026 - (JCN Newswire) - OMRON Healthcare Co., Ltd. today announced the launch of a randomized controlled trial in collaboration with the University of California, San Francisco (UCSF) to evaluate a new model for the early detection of atrial fibrillation (AFib) in hypertension patients using home blood pressure monitoring.

AFib is a common cardiac arrhythmia closely linked to aging and high blood pressure and is associated with a significantly elevated risk of stroke, heart failure, and cardiovascular mortality. However, up to 40% of individuals with AFib may experience no noticeable symptoms, allowing the condition to remain undiagnosed until serious complications occur.

The fully remote clinical study, entitled Out-of-office Monitoring for Rhythms Of Normal versus Atrial Fibrillation: A Randomized Controlled Trial (OMRON-AF Trial), will enroll approximately 1,900 hypertension patients aged 60 and older who have risk factors for atrial fibrillation from users of the OMRON Connect mobile app. Participants will be randomized into two groups: one using a home blood pressure monitor equipped with OMRON’s Intellisense AFib algorithm and the other using a standard monitor without AFib detection functionality.

In cases where potential signs of AFib are detected during routine home blood pressure monitoring, participants will receive a wearable patch electrocardiogram (ECG) device for confirmatory diagnosis. By integrating AFib screening into existing hypertension care pathways, the study aims to determine whether daily home blood pressure monitoring can improve early detection without increasing the burden on patients or healthcare systems.

Participants diagnosed with AFib will also be assessed for heart failure risk via NT-proBNP biomarker testing, while AF burden (percentage of time spent in atrial fibrillation during a given monitoring period) as measured via patch ECG will be analyzed against episode frequency recorded during home blood pressure monitoring in order to explore how home monitoring can support ongoing AFib management after diagnosis.

“This collaboration with UCSF represents an important step toward integrating atrial fibrillation screening into routine hypertension management,” said Ayumu Okada, President and CEO of OMRON Healthcare Co., Ltd. “By leveraging everyday home blood pressure monitoring habits, we aim to help reduce stroke and heart failure risk and advance our vision of ‘Going for ZERO.’”

Professor Gregory Marcus of UCSF added, “Unlike many other studies of various devices to screen for atrial fibrillation, we will be employing a randomized controlled trial, enabling a rigorous assessment that will test whether home blood pressure monitoring might be an effective tool to identify occult atrial fibrillation. This approach leverages common home-based evaluations that are already widely used in hypertension care. The study will also utilize remote recruitment and engagement, representing a particularly efficient approach that harnesses mobile app and smartphone-based technologies. We hope this research will help establish a new model for more appropriately identifying atrial fibrillation in high-risk patients with hypertension and linking them to diagnosis and treatment, while also generating evidence that can be implemented in real-world clinical practice.”

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026
Fatty Liver Disease: Connecting Metabolic Health With Liver CareNovember 12, 2026
Chronic Kidney Disease: Understanding Risk Assessment and Early MonitoringNovember 12, 2026
Advanced OCTA Diagnostics in Age-Related Macular Degeneration (AMD)November 11, 2026
Advanced Diagnostics in Age-Related Macular Degeneration (AMD): Optical Coherence Tomography Angiography (OCTA)November 11, 2026
PCOS Care in India: Understanding Diagnosis and Long-Term MonitoringNovember 11, 2026
Thyroid Health: Making Sense of Testing and Follow-UpNovember 11, 2026